Four things to know:
1. The financing will be used for general corporate purposes, a company spokesperson told the publication, adding that Sequoia Capital and NewView Capital led the investment round.
2. The new funding comes nearly a year after 23andMe announced layoffs of 100 employees due to decreasing sales of its direct-to-consumer DNA test kits.
3. At a conference earlier in December, 23andMe CEO Anne Wojcicki said more than 12 million of the company’s customers agreed to participate in drug discovery research, which helped support COVID-19 research.
4. More than one million people took 23andMe’s COVID-19 study, which found that people with O blood type are between 9 percent and 18 percent less likely than others to have tested positive for COVID-19.
More articles on consumerism:
Lyft, Anthem, others launch program for individuals needing rides to COVID-19 vaccine appointments
UnitedHealthcare launches Apple Fitness+ for health plan members
Amazon launches Halo for general public: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
